文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

寻找最合适的原位视网膜母细胞瘤小鼠模型以表征肿瘤发展

Looking for the Most Suitable Orthotopic Retinoblastoma Mouse Model in Order to Characterize the Tumoral Development.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

研究将人视网膜母细胞瘤组织经皮下移植建立肿瘤后,将细胞悬液视网膜下注射至免疫缺陷小鼠(Swiss-nude、SCID)和免疫健全小鼠(C57BL/6N、B6Albino)右眼建立原位模型,用眼底和SD-OCT监测并与组织学比较。SCID小鼠成瘤率最高(68.8%),B6Albino为50%,C57BL/6N未见肿瘤生长。作者认为SCID和B6Albino均可推荐用于建立原位视网膜母细胞瘤异种移植模型。

要点

  • SCID小鼠视网膜下注射后成瘤率最高,为68.8%。
  • 免疫健全B6Albino小鼠成瘤率为50%,可用于研究免疫反应。
  • C57BL/6N品系未见肿瘤生长。

核心结论

  • 原位小鼠模型的建立主要取决于移植细胞的选择,也可能取决于异种移植的小鼠品系。
  • SCID小鼠成瘤率最高(68.8%),免疫健全B6Albino小鼠成瘤率也令人满意(50%)。
  • 作者认为SCID和B6Albino两种品系均可推荐用于建立原位视网膜母细胞瘤异种移植模型。

研究设计与样本

  • 研究将去眼球的人视网膜母细胞瘤组织皮下移植至免疫缺陷小鼠建立肿瘤,再将细胞悬液视网膜下注射至免疫缺陷小鼠(Swiss-nude、SCID)和免疫健全小鼠(C57BL/6N、B6Albino)右眼建立原位模型。
  • 采用眼底和频域光学相干断层扫描(SD-OCT)成像监测活体肿瘤生长,并与组织学比较。

主要发现

  • 免疫健全和免疫缺陷品系在视网膜下注射肿瘤细胞后均可见视网膜和玻璃体肿瘤生长。
  • SCID小鼠成瘤率最高,为68.8%;B6Albino小鼠成瘤率为50%;C57BL/6N品系未见肿瘤生长。
  • 视网膜下注射后多数品系可能发生慢性视网膜脱离,尤其是Swiss-nude品系,该品系表现出视网膜变性。

临床怎么用

  • 作者认为SCID和B6Albino两种品系均可推荐用于建立原位视网膜母细胞瘤异种移植模型。
  • 作者指出B6Albino品系将允许利用肿瘤治疗后的免疫反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Because retinoblastoma therapies have many adverse effects, new approaches must be developed and evaluated on animal models. We describe orthotopic xenograft models of retinoblastoma using different strains of mice, suitable for this purpose. METHODS: Human retinoblastoma tumors were established on immunodeficient mice by subcutaneous engraftment of tumors from enucleated eyes. The orthotopic model was obtained by subretinal injections of suspension cells into the right eye of immunodeficient (Swiss-nude, severe combined immunodeficiency [SCID]) and immunocompetent mice (C57BL/6N, B6Albino). In vivo tumor growth was monitored by fundus and spectral-domain optical coherence tomography (SD-OCT) imaging and compared with histology. RESULTS: Retinal and vitreal tumor growth was achieved both in immunocompetent and immunodeficient strains after the subretinal injection of tumor cells. The best tumor engraftment rate was obtained in the SCID mice (68.8%). No tumor growth was observed in the C57BL/6N strain. Chronic retinal detachment may occur in most strains after the subretinal injection, in particular the Swiss-nude strain, which exhibits retinal degeneration. CONCLUSIONS: The setting up of an orthotopic mouse model depends mainly on the choice of the engrafted cells (cell lines or patient-derived xenografts) but it can also depend on the xenografted mouse strain. Severe combined immunodeficiency mice (an immunodeficient strain) achieved the best tumor engraftment rate (68.8%). However, intraocular tumor growth was also satisfactory (50%) in the immunocompetent strain B6Albino, and this strain will allow to exploit the immune response after a tumor treatment. Both of these strains may therefore be recommended when setting up orthotopic retinoblastoma xenografts.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Lemaitre S, Poyer F, Marco S, et al. Looking for the Most Suitable Orthotopic Retinoblastoma Mouse Model in Order to Characterize the Tumoral Development. Invest Ophthalmol Vis Sci. 2017. PMID: 28622397. doi:10.1167/iovs.17-21760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。